Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA by Tomaszuk-Kazberuk, Anna et al.
Address for correspondence: Dr. Łukasz Kołtowski, First Department of Cardiology, Medical University of Warsaw,  
ul. Banacha 1a, 02–097 Warszawa, Poland, tel: +48 22 599 19 51, fax: +48 22 599 19 50, e-mail: lukasz@koltowski.com
Use of non-vitamin K antagonist oral anticoagulants 
(NOACs) in patients with atrial fibrillation  
— Messages from the 2018 EHRA
Anna Tomaszuk-Kazberuk1, 2, Łukasz Kołtowski1, 3, Paweł Balsam1, 3, Marek Koziński1, 4, 
Agnieszka Kapłon-Cieślicka1, 3, Karolina Kupczyńska1, 5, Justyna Domienik-Karłowicz1, 6, 
Anna Budaj-Fidecka1, 3, Piotr Buszman1, 7, 8, Maciej Wybraniec1, 9, Paweł Burchardt1, 10, 11, 
Błażej Michalski1, 5, Miłosz J. Jaguszewski1, 12
1Club 30, Polish Cardiac Society, Poland 
2Department of Cardiology, Medical University of Bialystok, Poland  
3First Department of Cardiology, Medical University of Warsaw, Poland 
4Department of Principles of Clinical Medicine, Collegium Medicum,  
Nicolaus Copernicus University, Bydgoszcz, Poland 
5Department of Cardiology, W. Bieganski Hospital, Medical University of Lodz, Poland 
6Department of Internal Medicine and Cardiology with the Center for Diagnosis and Treatment  
of Venous Thromboembolism, Medical University of Warsaw, Poland 
7Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland 
8Third Clinical Department of Cardiology, Silesian Center for Heart Diseases,  
Medical University of Silesia, Zabrze, Poland 
9First Department of Cardiology, School of Medicine in Katowice,  
Medical University of Silesia, Katowice, Poland 
10Department of Biology and Lipid Disorders, Poznan University of Medical Sciences, Poznan, Poland 
11Department of Cardiology, J. Strus Hospital, Poznan, Poland 
12First Department of Cardiology, Medical University of Gdansk, Poland
Introduction
Non-vitamin K antagonist oral anticoagulants 
(NOACs) were developed and approved as sub-
stitutes for vitamin K antagonists (VKAs) [1–3]. 
NOACs have become the preferred treatment 
strategy in patients with eligible atrial fibrillation 
(AF) based on their favorable efficacy/safety pro-
file, predictable effect without the need for rou-
tine coagulation monitoring together with fewer 
food and drug interactions when compared with 
VKAs [1, 4–6]. As the results of new clinical trials 
are released and clinical experience with NOACs 
expands, new recommendations in this field are 
published [1, 3, 4]. Recently, the 2018 European 
Heart Rhythm Association (EHRA) Practical 
Guide on the use of NOACs in the setting of AF, 
the second update of this clinical practice-guiding 
document, has been published [1].
This review aims to present highlights of the 
recent update of the Practical Guide, with a particular 
emphasis on changes and new aspects when com-
pared with its previous versions [1–3]. This manu-
script, similarly to the discussed expert consensus, 
considers several key clinical scenarios for which 
evidence-based recommendations were framed.
Use of NOACs in valvular heart disease: 
Eligibility for NOACs
In patients with AF, NOACs are recommended 
in the prevention of stroke and systemic throm-
boembolism in a vast majority of patients at risk, 
excluding only patients who underwent implanta-
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tion of a mechanical prosthetic valve and those with 
moderate to severe mitral stenosis, usually due 
to rheumatic heart disease [4, 7]. The former AF 
patients with valvular heart disease (VHD) are clas-
sified as functional EHRA (Evaluated Heartvalves, 
Rheumatic or Artificial) type 1 and require therapy 
with a VKA [4, 6, 7]. On the other hand, the EHRA 
type 2 category includes patients with all other 
types of VHD, after mitral valve repair, biopros-
thetic valve replacement and transcatheter aortic 
valve implantation (TAVI) [7]. Such AF patients 
were at least to some extent enrolled in landmark 
NOAC trials (e.g. valvular regurgitations or sten-
oses other than moderate- to severe mitral steno-
sis, patients > 3 months after bioprosthetic valve 
implantation or mitral valve repair) or there is no 
rationale against therapy with NOAC (e.g. patients 
after TAVI procedures) [8–12]. Therefore, the 
EHRA experts conclude that these patients may be 
treated either with a VKA or with a NOAC [1, 4, 7]. 
One exception are AF patients with a biological 
mitral prothesis implanted for rheumatic stenosis. 
Due to typical enlargement and structural changes 
of atria in this setting, VKAs may be the preferred 
option over NOACs (Table 1) [1]. Additionally, de-
spite few data supporting such management [13, 
14], the EHRA experts believe that AF patients 
with hypertrophic cardiomyopathy and indications 
for anticoagulation may benefit from NOACs [1].
Use of EHRA NOAC card, careful dose  
reduction criteria: Pre-specified  
follow-up schedule for patients  
on NOACs
Anticoagulation therapy in AF patients should 
be initiated ensuring a balance between the risk and 
benefit [4]. Subsequently, the choice of particular an-
ticoagulant (NOAC or VKA) should be advocated by 
guidelines of professional societies and indications 
approved by regulatory authorities [1]. European 
guidelines generally prefer NOACs over VKAs in ma-
jority AF patients (class I, level of evidence A) [4]. 
However, before initiation of any anticoagulant kid-
ney function should be assessed and then monitored 
if NOAC therapy is started. Additionally, all product 
characteristics, patient-related factors, and patient 
preferences should be considered when choosing 
a particular treatment strategy [15, 16]. 
Importantly, EHRA experts emphasize that 
standard NOAC doses, tested in large randomized 
trials, should be used in clinical practice [1]. In fact, 
only in RE-LY and ENGAGE-AF were adequately 
powered to test both lower
 
and higher NOAC doses 
[3, 9, 17]. Thus, in the clinical practice, we should 
follow the dose reduction criteria investigated in the 
fully powered randomized clinical trials (RCTs) [1, 4].
Notably, proton pump inhibitors are proposed 
in the EHRA guide as protective agents aimed 
to reduce the event rates of gastrointestinal (GI) 
bleeding related to NOAC therapy [1]. In particular, 
they may be considered in patients with known 
ulcer or previous GI bleeding, as well as those 
on concomitant dual antiplatelet therapy [18–22]. 
However, data on this gastroprotective effect in 
patients treated with NOACs are limited [1].
Education of patients on NOACs at each visit 
is critically important [23, 24]. Crucial aspects of 
education comprise: i) intake modalities, i.e. once 
daily or twice a day, intake with food in case of rivar-
oxaban, ii) the key role of rigorous adherence to the 
prescribed therapy, iii) how to deal with any lapse in 
dosing, and iv) to be careful not to leave their medi-
cation behind when travelling. NOAC-treated pa-
tients, similarly to those on VKAs, should possess an 
anticoagulation card [1, 4, 16]. The updated NOAC 
card proposed by EHRA experts will be available 
soon in different languages at www.NOACforAF.eu. 
This uniform card contains information on the used 
NOAC regimen (e.g. name of anticoagulant, dosing, 
timing, with or without food), treatment indication, 
date when treatment was started, concomitant medi-
cations, name and address of physician coordinating 
NOAC treatment, emergency situations (e.g. contact 
to patient relatives, patient blood group), planned 
or unplanned visits, recommended follow-up with 
a checklist, results of hemoglobin concentration as 
well as kidney and liver tests [1–3].
The follow-up of patients on NOACs has to 
be cautiously planned, specified and communi-
cated among the different caregivers [4, 25–27]. 
Medical therapy of NOAC users should be regularly 
reviewed, preferably the first time 1 month after 
drug initiation and then at least every 3 months. 
A structured follow-up of NOAC-treated patients 
proposed by EHRA experts is shown in Figure 1. 
The authors of the recent EHRA Practical Guide 
also updated and expanded the recommended 
checklist during the follow-up contacts of AF pa-
tients on anticoagulation (Table 1) [1, 3].
Adherence to prescribed therapy:  
Strict adherence plays a key role
NOAC’s anticoagulant effect diminishes af-
ter 12–24 hours which makes strict adherence to 
drug intake a critical issue [28]. Importantly, NOAC 
plasma concentrations and general coagulation tests 
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reflect drug intake over the last 24–48 hours and 
therefore they cannot be considered tools to moni-
tor adherence to therapy [29]. Regular follow-up 
assessment with a pre-specified schedule together 
with education of patients and their families is the 
preferred strategy to facilitate adherence to NOAC 
therapy [15, 16, 23, 24, 28, 30]. Other possible 
tools potentially improving adherence are the use 
of pharmacy databases to monitor adherence, im-
plementation of technological aids (e.g. medication 
boxes, smartphone/watchOS applications) [31–33], 
and preference of once daily dosing regimens over 
BID regimens [34–36].
Switching between anticoagulant regimens
Appropriate switching between anticoagu-
lants aims at balancing between both thrombotic 
and bleeding risks. Six clinical scenarios may be 
considered: 1) switching from a VKA to a NOAC; 
2) switching from a NOAC to a VKA; 3) switch-
ing from a NOAC to parenteral anticoagulants;   
4) switching from a parenteral anticoagulant to 
a NOAC; 5) switching from one NOAC to another 
NOAC; and 6) switching from an antiplatelet drug 
to a NOAC (Fig. 2) [1]. All recommendations are 
based on the current knowledge regarding phar-
macokinetics and pharmacodynamics of anticoagu-
lants. Regarding the above listed situations:
1. NOAC should be initiated immediately when 
international normalized ratio (INR) value is 
< 2.0. In patients with INR 2.0–2.5, NOAC 
may be started immediately or (preferentially) 
the next day. For INR values exceeding 2.5, 
INR should be re-checked within 1–3 days. 
Table 1. Checklist during follow-up contacts of atrial fibrillation patients on anticoagulation. Reprinted 
with permission from: Eur Heart J. 2018; 39(16): 1330–1393.
Interval Comments
1. Adherence Each visit •	 Instruct patient to bring NOAC card and complete list of medication: 
make note and assess average adherence
•	Re-educate on importance of strict intake schedule
•	 Inform about adherence aids (e.g. special boxes; smartphone  
applications). Consider specific adherence measuring interventions  
(e.g. review of pharmacy refill data; electronic monitoring;  
special education session)
2. Thromboembolism Each visit •	Systemic circulation (TIA, stroke, peripheral)
•	Pulmonary circulation
3. Bleeding Each visit •	 ‘Nuisance’ bleeding: preventive measures possible?  
Motivate patient to diligently continue anticoagulation
•	Bleeding with impact on quality-of-life or with risk: prevention possible? 
Need for revision of anticoagulation indication, dose or timing?
4. Other side effects Each visit Carefully assess relation with NOAC: decide for continuation  
(and motivate), temporary cessation, or change of anticoagulant drug
5. Co-medications Each visit •	Prescription drugs; over-the-counter drugs
•	Careful interval history: also temporary use can be risky
6. Blood sampling (incl. 






Patients other than those specified below
≥ 75 years (especially if on dabigatran) or frail
If renal function CrCl ≤ 60 mL/min: recheck interval = CrCl/10
If intercurrent condition that may impact renal or hepatic function
7. Assessing and  
minimizing modifiable 
risk factors for bleeding
Each visit •	As recommended by current guidelines
•	Particularly: uncontrolled hypertension (systolic > 160 mmHg),  
medication predisposing for bleeding (e.g. ASA, NSAIDs), labile INR  
(if on VKA), excessive alcohol intake)
8. Assess for optimal 
NOAC and correct  
dosing
Each visit Especially based on the above, re-assess whether
•	The chosen NOAC is the best for the patient
•	The chosen dose is correct
ASA — acetylsalicylic acid; CrCl — creatinine clearance (preferably measured by the Cockcroft-Gault method); INR — international normalized 
ratio; NOACs — non-vitamin K antagonist oral anticoagulans; NSAIDs — non-steroidal anti-inflammatory drugs; TIA — transient ischemic  
attack; VKAs — vitamin K antagonists
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The estimated time when INR drops below 
this threshold depends on the current INR 
and the half-life of the VKA (half-lives for 
acenocoumarol, warfarin and phenprocoumon 
are 8–24 h, 36–48 h and 120–200 h, respec-
tively) [1].
2. Due to the delayed onset of VKA action, it 
may take 5–10 days until INR achieves the 
therapeutic range. Therefore, both drugs 
should be used concomitantly until therapeutic 
INR values are obtained. Loading doses are 
recommended neither for acenocoumarol nor 
for warfarin but remain appropriate for phen-
procoumon [1, 37–39].
3. Both unfractionated heparin (UFH) and low mo-
lecular weight heparin (LMWH) can be started 
at the time of next scheduled dose of NOAC [1].
4. NOACs can be initiated 2–4 hours after intra-
venous infusion of UFH is stopped. NOACs 
can be started when the next dose of LMWH 
is scheduled [1].
5. An alternative NOAC can be started when the 
following dose of the initial NOAC is planned 
unless overdose of the initial NOAC is ex-
pected. In such case, a longer interval between 
doses of NOACs is recommended [1].
6. NOAC may be initiated immediately when 
either acetylsalicylic acid (ASA) or clopidogrel 
Figure 1. Initiation and follow-up visits of patients on non-vitamin K antagonist oral anticoagulants (NOACs) — a simpli- 
fied scheme. Dependent on local situation, follow-up may be performed by general practitioners or specialists. 
*hemoglobin, liver/renal function, coagulation panel; PPI — proton pump inhibitor. Adapted from: Eur Heart J. 
2018; 39(16): 1330–1393. 
Figure 2. Switching between anticoagulant regimes; *half dose for edoxaban; **loading dose for phenprocoumon; 
***before NOAC intake; INR — international normalized ratio; NOAC — non-vitamin K antagonist oral anticoagulant; 
VKA — vitamin K antagonist. Adapted from: Eur Heart J. 2018; 39(16): 1330–1393.
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is stopped. However, in some AF patients (e.g. 
undergoing percutaneous coronary interven-
tion [PCI] with stent implantation) combina-
tion therapy is required [1].
Pharmacokinetics and drug–drug  
interactions of NOACs:  
Check drug–drug interactions
Detailed description of pharmacokinetics of 
different NOACs remains beyond the scope of the 
present review. Despite fewer food and drug–drug 
interactions of NOACs vs. VKAs, pharmacokinetic 
interactions of the former agents with other drugs 
and comorbidities should be considered by the 
treating physicians [1]. Absorbtion, metabolism, 
distribution, as well as excretion of NOACs have 
been described in detail previously [3]. An essential 
mechanism responsible for drug–drug interac-
tions involving NOACs is GI re-secretion over 
a P-glycoprotein (P-gp) transporter after absorption 
in the gut. Competitive inhibitors of this pathway, 
i.e. verapamil, dronedarone, amiodarone, and qui-
nidine, increase plasma levels of NOACs [40, 41]. 
Notably, hepatic clearance of rivaroxaban and 
apixaban depends on CYP3A4-type cytochrome 
P450-mediated elimination. Therefore, strong 
inhibition or induction of CYP3A4 may affect 
plasma concentrations of these NOACs [42–44]. 
In principle, NOACs should not be administered 
in combination with CYP3A4 and P-gp inhibi-
tors, i.e. dronedarone, itraconazole, ketoconazole, 
voriconazole [45, 46]. On the other hand, strong 
inducers of P-gp and/or CYP3A4, i.e. rifampicin 
or carbamazepine, substantially decrease NOAC 
levels in plasma and such combinations should be 
avoided or used carefully [1, 47–49].
Importantly, rivaroxaban for stroke prevention in 
AF should be administered with food. Otherwise its 
bioavailability is substantially impaired [44]. Neverthe-
less, no food interactions were documented with other 
NOACs exposure as tablet formulation [50–52]. Last 
but not least, dabigatran capsules must not be opened 
since it may result in a considerable increase in its 
bioavailability [51, 53].
In summary, potential drug–drug interactions, 
especially in combination with other clinical risk 
factors, influencing NOAC levels in plasma are 
crucial for selecting the most appropriate NOAC-
therapy and/or a ‘reduced dose’ for a specific patient 
[41, 42, 54, 55]. More detailed information on NOAC 
interactions is provided in the recent update of the 
Practical Guide and in summaries of product char-
acteristics [1]. 
NOACs in patients with chronic kidney 
disease or advanced liver disease: Assess 
kidney function, creatinine clearence! 
Both kidneys and liver are substantially 
involved in the metabolism and elimination of 
NOACs. Kidney function should be assessed at 
least once a year in patients on NOACs in order to 
adapt the drug dose if necessary. In patients with 
reduced creatinine clearance (CrCl), i.e. ≤ 60 mL/ 
/min, it is recommended to assess kidney func-
tion more frequently. Importantly, CrCl should be 
preferably assessed by using the Cockroft-Gault 
method and the minimum frequency of kidney 
function evaluation in months may be calculated 
by dividing CrCl by 10 [1, 4].
All four NOACs demonstrated comparative 
efficacy and safety in patients with mild to moder- 
ate chronic kidney disease (CKD), i.e. CrCl 
≥ 30 mL/min, when compared with warfarin 
[56–61]. In cases with CrCl 30–50 mL/min, dosing 
of NOACs should be adapted as follows: 
 — dabigatran — 150 mg BID or 110 mg BID in 
patients at high risk of bleeding;
 — rivaroxaban — 15 mg QD;
 — edoxaban — 30 mg QD;
 — apixaban — 2.5 mg BID if at least two out of 
three criteria are fulfilled: age ≥ 80 years, body 
weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL. 
Rivaroxaban, apixaban, and edoxaban, but 
not dabigatran, are approved in Europe in cases 
with severe CKD, i.e. CrCl of 15–29 mL/min, at 
reduced doses: 
 — rivaroxaban — 15 mg QD;
 — edoxaban — 30 mg QD;
 — apixaban — 2.5 mg BID. 
In contrast, all NOACs are contraindicated 
in patients with a CrCl of ≤ 15 mL/min and on 
dialysis (Table 2) [1].
Advanced liver disease is associated with 
impaired blood coagulation resulting in increased 
bleeding risk. However, it may also lead to throm-
botic complications [62]. Additionally, severe liver 
dysfunction can strongly affect hepatic clearance 
and drug metabolism [63]. Contraindications to 
NOACs include coagulopathy associated with 
hepatic disease and clinically relevant bleeding 
risk [1, 17, 64–66]. Rivaroxaban is contraindicated 
in patients with Child-Turcotte Pugh B cirrhosis 
[67]. Finally, initiation of NOAC therapy in cases 
with advanced liver disease and their follow-up 
is recommended at a specialized center in a mul-
tidisciplinary team, including a hepatologist and 
a hematologist [1].
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How to measure the anticoagulant effect 
of NOACs? No need for routine plasma 
levels assessment
Although the results of standard coagulation 
tests, including prothrombin time (PT) and activat-
ed partial thromboplastin time (aPTT), are affected 
by NOACs, these tests generally do not accurately 
reflect NOAC anticoagulant effects. Nevertheless, 
specific coagulation assays are available to quan-
tify NOAC levels in plasma [29, 68, 69]. Hospitals 
should consider 24/7 availability of these particular 
assays, especially in emergency situations. Most 
routine coagulometers are capable of measuring 
NOAC plasma levels within 30 minutes [1]. Anti- 
-FXa chromogenic assays reliably measure plasma 
concentrations of FXa inhibitors. Importantly, 
unmeasurable anti-Xa activity rules out clinically 
relevant drug levels. Both, ecarin chromogenic 
assay (ECA) and diluted thrombin time (dTT) test 
are proportional to dabigatran blood concentrations 
and can be used for quantitative assessment [1]. 
When interpreting the result of a coagulation assay 
in a patient on NOAC, it is critical to know the time 
of NOAC administration and its relation to blood 
sampling. Importantly, the most pronounced effect 
of a NOAC on the clotting test takes place simul-
taneously with its peak plasma concentration, i.e. 
1–3 hours after NOAC intake [44, 70–75].
NOAC plasma level measurements may 
be considered in emergencies/complex 
patient profiles and under expert  
guidance: Rare indications, precautions 
and potential pitfalls
As mentioned above, the routine measurement 
of plasma NOAC concentration to guide therapy is 
discouraged and should be performed in particu-
lar situations of potentially essential interactions 
or specific scenarios, including emergencies. Ad-
ditionally, these tests should be done in centers 
with vast experience in the interpretation and 
performance of such measurements [1].
Emergencies
In emergencies, i.e. bleeding, acute stroke, 
suspected overdosing, intoxication or in patients 
undergoing urgent procedures, routine coagula-
tion tests provide a quick information on recent 
exposure, while specific assays inform us on ac-
curate assessment of plasma NOAC levels [29, 
68, 69, 76]. 
Information on drug exposure may determine 
the optimal timing of procedure in case of urgent 
surgery or in planned surgery in patients at high-
bleeding risk. Furthermore, coagulation assays 
may guide thrombolytic therapy, for instance, in 
cases with acute ischemic stroke [68, 72, 77–79].
Elective procedures
The current EHRA Guide does not recom-
mend routine measurement of NOAC antico-
agulant activity before elective procedures [1]. 
Potential  exceptions to this role include: 
i) situations when the time from the last dose is 
unknown or uncertain, or ii) in case of potential 
drug–drug interactions or change in renal/hepatic 
function, based on concerns on the clearance of 
the drug [1, 80, 81].
Factors influencing pharmacokinetics
Measurement of plasma NOAC concentration 
may be also considered in patients at high risk, i.e. 
very lean or obese patients, uncontrolled cancer 
patients receiving therapy for malignancies, espe-
cially in case of unclear/unknown pharmacokinetic 
interactions [44, 70–75, 77].
Table 2. Non-vitamin K antagonist oral anticoagulants and renal function. Adapted from: Eur Heart J. 
2018; 39: 1330–1393.
Creatinine clearance Dabigatran Rivaroxaban Edoxaban Apixaban
> 95 mL/min 2 × 150 mg 20 mg 60 mg 2 × 5 mg or 2 × 2.5 mg***
50–95 mL/min 2 × 150 mg 20 mg 60 mg** 2 × 5 mg or 2 × 2.5 mg***
30–50 mL/min 2 × 150 mg or 2 × 110 mg* 15 mg 30 mg 2 × 5 mg or 2 × 2.5 mg***
15–30 mL/min No 15 mg 30 mg 2 × 2.5 mg
Dialysis No No No No
*2 × 110 mg in patients at high risk of bleeding. **consider additional dose reduction criteria (body weight £ 60 kg, concomitant use of  
P-glycoprotein inhibitor). ***2 × 2.5 mg if 2 out of 3 fulfilled: age ≥ 80 years, body weight £ 60 kg, creatinine > 1.5 mg/dL. Pink backgrounds 
= cautionary use.
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Problem solving: Dosing errors,  
overdose without bleeding  
or potential risk of bleeding
Overdose without bleeding
Overdose of NOAC can be a significant clini-
cal problem. In patients with a suspected NOAC 
overdose, coagulation tests are suitable to set 
its degree and potential risk of bleeding [29, 68, 
69]. Notably, aPTT result within limits of normal 
practically excludes high levels of dabigatran [72]. 
A normal PT excludes high levels of edoxaban and 
rivaroxaban [68]. However, these widely available 
coagulation tests should not be used for a quantita-
tive estimation of high NOAC concentrations [1]. If 
a more aggressive normalization of plasma levels is 
necessary, or rapid normalization is not expected 
because of major renal failure the measures used 
in the management of bleedings may be considered 
(e.g. administration of a specific reversal agent) 
[1, 2, 82–85].
Management of bleeding under NOACs: 
Nuisance bleeding, minor bleeding and 
non-life-threatening major bleeding
Nuisance and minor bleeding
Nuisance bleedings are very often disregarded 
both by cardiologists and general practitioners, 
although they are a frequent cause of interruptions 
of treatment. Majority of these bleeds can be man-
aged conservatively, i.e. by delaying NOAC intake 
or withholding its dose. Minor bleedings frequently 
require more aggressive management focused on 
the cause of bleeding. Epistaxis and gum bleeds 
should be managed using local anti-fibrinolytics. 
Recurrent minor bleeding events without causal 
therapeutic options should be treated using oth-
er NOAC with a potentially different bleeding 
profile, although we have no solid data on this 
subject [1, 4].
Non-life-threatening major bleeding
In case of a non-life-threatening major bleed-
ing the use of antifibrinolytics, i.e. tranexamic 
acid, 1 g i.v., repeated every 6 hours if needed or 
desmopressin 0.3 g/kg i.v. infusion with a maximal 
dosing of 20 g — especially in specific scenarios 
with associated coagulopathy or thrombopathy 
— may be considered. Tranexamic acid is ef-
ficacious to support hemostasis, particularly in 
trauma-induced bleeding, with a favourable safety 
profile [86–88].
Patients on dabigatran with  
life-threatening bleedings:  
The role of idarucizumab
Life-threatening bleedings
The most relevant changes have been in-
troduced in measures concerning life-threat-
ening bleedings. Patients on NOACs with such 
type of bleeding benefit from its reversal. In the 
REVERSE-AD study, fragment of humanized 
monoclonal antibody, idarucizumab was success-
fully implemented in patients on dabigatran with 
life-threatening bleedings, or with the necessity of 
a major life-saving emergency surgery [82, 83, 89]. 
Since anticoagulant effect of dabigatran can be fully 
reversed by idarucizumab within minutes, the use 
of 5 g idarucizumab administered intravenously in 
two bolus doses of 2.5 g no more than 15 minutes 
apart, is recommended as first choice of therapy 
in case of life-threatening bleeding. After 24 hours 
dabigatran can be effectively re-initiated if clinically 
indicated (Fig. 3) [82, 83, 89, 90].
Recently, new data were reported on the pos-
sibility of direct reversal of apixaban, edoxaban, 
or rivaroxaban. Andexanet alpha, based on the 
ANNEXA-4 study [83, 84] may become the first 
line therapy in life-threatening bleeding under 
FXa-inhibitor therapy. Although approved in USA, 
its regulatory approval and availability are pending 
in Europe. Thus, the direct reversal of FXa-inhibi-
tors remains unavailable in clinical settings [91]. In 
the ANNEXA-4 study, which includes exclusively 
patients with major or life-threatening bleeding, 
the drug is given as a bolus over 15–30 minutes, 
followed by a 2-hour infusion. The dosing depends 
on the kind of NOAC-therapy and on the timing 
since last intake [84]. Nevertheless, anticoagulant 
activity may re-appear after stopping the infusion. 
Thus, it is actually unknown at which point in time 
and with which anticoagulant effect FXa inhibitors 
or heparin should be re-administered following 
andexanet alpha use.
Data coming from RCTs and registries inves-
tigating NOACs have demonstrated that adminis-
tration of coagulation factors such as prothrombin 
complex concentrate (PCC) or activated PCC 
(aPCC) are rarely needed [91, 92]. Antagonizing 
the effect of NOAC has to be considered very 
carefully because of possible prothrombotic effect 
[93–99]. On the other hand, in cases with severe/ 
/life-threatening bleedings with no clear second-
ary/reversible/treatable cause the potential risks 
of re-initiating anticoagulation may outweigh the 
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benefits of NOAC therapy [1]. In such situations, 
percutaneous or surgical left atrial appendage 
occlusion may be considered as a valuable option 
instead of long-term anticoagulation [1, 4, 100]. 
Finally, whether the use of PCC or aPCC is useful 
in NOAC-related intracranial bleeding is still hotly 
debated [101–104] since a multicentre analysis 
did not reveal a significant benefit on hematoma 
enlargement [105]. In patients with intracranial 
bleeding caused by dabigatran, reversal of the 
anticoagulant effect is possible by infusion of re-
versal agent, idarucizumab. Hematoma growth was 
observed in 2 out of 12 patients with intracranial 
bleeding treated with dabigatran receiving idaru-
cizumab on hospital admission [106].
Patients presenting with acute stroke: 
Use of endovascular thrombectomy is  
a ‘first-line treatment’ in selected cases
The incidence of stroke ranges from 1% to 2% 
in the subset of AF under anticoagulation therapy. 
Both assessment of adherence to NOAC therapy 
and measurement of anticoagulant plasma level on 
admission remains crucial to optimize the second-
ary prevention strategy [107]. 
Thrombolytic therapy after NOAC
Revolutionary data were shown on manage-
ment of the acute course of ischemic stroke in 
AF patients treated with NOAC. According to the 
nowadays recommendations thrombolytic therapy 
with the use of recombinant tissue plasminogen 
activator (rt-PA) cannot be given on full anticoagu-
lation and/or within 24 hours (or longer in case of 
renal insufficiency, in elderly, etc.) after the last 
dose of a NOAC due to their plasma half-lives and 
the risk of uncontrolled bleedings [108]. This rec-
ommendation does not apply to dabigatran because 
of the availability of idarucizumab [83]. According 
to the REVERSE-AD trial, idarucizumab acts in-
stantly, completely and durably. After reversal and 
assessment of coagulation status, thrombolysis i.v. 
within 4.5 hours of onset of moderate to severe 
stroke seems feasible and safe [106, 109]. It is 
unknown yet if the same approach will be safe and 
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Figure 3. Management of bleeding in patients on non-vitamin K antagonist oral anticoagulants (NOACs); aPCC — acti-
vated prothrombin complex concentrate; PCC — prothrombin complex concentrate; RBC — red blood cell. Reprinted 
with permission for: Eur Heart J. 2018; 39(16): 1330–1393.
effective also for Xa-inhibitors once andexanet 
alpha becomes available [1]. Last but not least, the 
use of rt-PA may be considered after NOAC intake 
when NOAC specific coagulation measurement 
is performed and/or time frame of the last dose 
is known [110–112]. Thus, as mentioned above, 
the easy-to-use point-of-care testing should be 
available 24/7 for emergency situations (currently 
possible in a minority of labs) [1].
Endovascular thrombectomy
The benefits of endovascular thrombectomy 
performed within 7.3 hours from symptom onset 
have been documented in non-anticoagulated 
patients having occlusion of a distal portion of 
internal carotid artery or proximal middle cer-
ebral artery [113]. The eventual effect of present 
anticoagulation on reperfusion related risk of 
bleeding must be considered in patients on NOACs 
presenting with ischemic stroke. An alarmingly 
high rate of asymptomatic hemorrhagic transfor-
mation was reported in a recent registry including 
28 patients with stroke on NOACs undergoing me-
chanical recanalization [114]. Currently, although 
endovascular thrombectomy is set as a ‘first line 
strategy’ in a subset with contraindication for 
thrombolytic therapy by the European Stroke Or-
ganization [115], the American Heart Association 
provided no recommendation in this regard [108], 
thus, more prospective studies are warranted to 
support mechanical recanalization. 
No need for bridging: Planned invasive 
procedures, surgery, or ablations 
Minor bleeding risk
In most minor surgical procedures, i.e. dental 
interventions, cataract or glaucoma intervention, 
endoscopy without biopsy, superficial surgery, 
and procedures with controllable bleeding, oral 
anticoagulation should not be interrupted. Above-
mentioned procedures may be performed 12–24 
hours after the last NOAC intake and restarted 
6 hours after the procedure [1].
Low bleeding risk
In case of low-bleeding-risk-procedures, i.e. 
cardiac device implantations, endoscopy with biop-
sy, prostate or bladder biopsy, electrophysiological 
study or catheter ablation, excluding complex pro-
cedures, performed in patients with normal kidney 
function, it is recommended to take the last NOAC 
dose of 24 hours before the elective procedure 
[1, 116]. It is important to check the kidney func-
tion and to adapt the time of NOAC withdrawal.
High bleeding risk
In high-risk major bleeding invasive proce-
dures, i.e. spinal or epidural anaesthesia, lumbar 
diagnostic puncture, thoracic surgery, abdominal 
surgery, major orthopedic surgery, liver or kidney 
biopsy, transurethral prostate resection, it is rec-
ommended to take the last NOAC dose 48 hours 
or longer before surgery [1].
Importantly, preoperative bridging with LMWHs 
or UFH is not recommended in patients treated 
with NOACs [1, 117, 118]. In case of immediate 
and complete hemostasis, NOACs can usually be 
resumed 6–8 hours after the end of the intervention. 
Notably, restarting full dose anticoagulation within 
the first 48–72 hours after the procedure is associ-
ated with substantial bleeding risk and in individual 
patients this risk may exceed the prothrombotic 
risk. In general, initiation of post-operative throm-
boprophylaxis 6–8 hours after surgery and resuming 
a NOAC 48–72 hours after operation, but as soon as 
possible, can be considered (Table 3) [1].
Anticoagulation in the setting of AF abla-
tions remains a difficult problem. On one hand, an 
increased risk of thromboembolic complications 
exists in these patients, on the other there is 
a substantial risk of bleeding during the procedure 
[119, 120]. The last NOAC dose should be admin-
istered 12 hours before AF ablation, especially if 
transseptal puncture is to be performed without 
periprocedural imaging. The results of the ongo-
ing Perioperative Anticoagulant Use for Surgery 
Evaluation (PAUSE) study are awaited. This large 
prospective cohort study (n = 3291) aims to deter-
mine how to optimally manage NOAC-treated AF 
patients undergoing elective surgical or interven-
tional procedures (PAUSE; NCT02228798) [121].
Urgent surgical intervention
All patients requiring urgent surgery should 
stop NOAC immediately. Three categories of 
intervention have been proposed: 1) immediate 
procedures, 2) urgent procedures, and 3) expe-
dite procedures [1]. In case of dabigatran-treated 
patients, who require life-, limb-, organ-saving 
procedure (immediate procedure) within min-
utes, it is recommended to consider reversal with 
idarucizumab [83, 122]. If dedicated agent is not 
available, administration of PCC or aPCC is advised 
despite lack of evidence [102, 117, 123]. Urgent 
and expedite procedures should be deferred, if pos-
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sible, until 12–24 hours after last dose [1]. Routine 
coagulation tests cannot exclude drug levels for all 
of the NOACs, though normal aPTT for dabigatran 
and normal PT for rivaroxaban exclude high levels 
of these drugs. Plasma levels and specific coagula-
tion tests (dTT/ECA for dabigatran and anti-FXa for 
factor Xa inhibitors) provide close understanding 
of coagulation status [1].
Use of NOACs in combination with  
antiplatelet therapy as a preferred  
strategy: Patients with AF and  
coronary artery disease
So far there was lack of large outcome trials 
comparing VKAs and NOACs in patients with AF 
undergoing PCI for acute coronary syndromes or for 
stable coronary artery disease, in particular subset 
treated with single- or dual-antiplatelet therapy 
[124]. New data coming from randomized clinical 
trials on NOACs post-PCI have emerged. There 
are two large studies addressing this topic, namely 
PIONEER AF-PCI [125] and RE-DUAL PCI [126]. 
The first one compared two rivaroxaban dosages to 
VKA and double antiplatelet therapy for 12 months 
(n = 2124), and showed that rivaroxaban lowered 
the risk of clinically relevant bleeding complications 
compared to VKA, irrespective of double antiplatelet 
therapy combination. The limitation of this trial were 
the dosages of rivaroxaban (i.e. 2.5 mg and 15 mg) 
that have not been validated for stroke prevention 
in the Caucasian population [125]. The RE-DUAL 
PCI evaluated two doses of dabigatran (110 mg and 
150 mg BID) in combination with clopidogrel or 
ticagrelor (dual therapy) vs. standard triple therapy 
with VKA, ASA and clopidogrel or ticagrelor in 
a subset of AF undergoing PCI with stent implanta-
tion (n = 2725). Dual therapy strategy with of both 
doses of dabigatran reduced non-major and major 
bleeding events compared to triple therapy, and was 
non-inferior (110 mg) or superior (150 mg) to VKA 
for prevention of cerebral ischemic events [126]. 
There is no more support for using bare metal 
stent in coronary artery disease to shorten the dura-
tion of P2Y12 therapy in patients on NOACs [1, 4, 18]. 
The use of new P2Y12 inhibitors (ticagrelor, prasugrel) 
in triple therapy is discouraged (class III, level of 
evidence C) [4, 18]. However, it is possible to use 
antiplatelet agents in combination with NOAC in dual 
therapy (without ASA) in patients with high throm-
botic risk, acute coronary syndromes, or previous 
stent thrombosis [1]. Shortening of triple therapy 
is now the preferred strategy. In patients with high 
ischemic risk, triple therapy should be continued for 
1–6 months (depending on bleeding risk) with subse-
quent dual therapy until 1 year [127, 128]. There is a 
general agreement among the EHRA experts not to 
extend triple therapy beyond 6 months [1].
Cardioversion in patients treated  
with NOACs
In patients with AF lasting > 48 hours (or of 
unknown duration) undergoing cardioversion, effec-
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Table 3.  Non-vitamin K antagonist oral anticoagulant (NOAC) treatment strategy before atrial fibril-
lation (AF) ablation. Rule out left atrium/left atrial appendage thrombus prior to ablation if ≥ 36 hours 
without NOAC, if there is doubt about compliance, or in high thromboembolic risk. Target activated 
clotting time during ablation: 300–350 s. Adapted from: Europace 2018; 20(8): 1231–1242.
Last intake of NOAC (–)24 to (–)12 hours Prior to planned AF ablation
Factors to shorten interruption — High CHA2DS2-VASc score ≥ 3
— No heparin i.v. prior to 1st TSP
— Operator experience
— Imaging for transseptal puncture
— Large left atrium
Factors to lenghten interruption — Low CHA2DS2-VASc score £ 2
— Heparin i.v. prior to 1st TSP
— Limited operator experience
— No imaging for transseptal puncture
— Normal size left atrium
— Reduced renal function
Reasumption 3 to 5 hours after the procedure Rule out tamponade and other  
major bleeding prior to restarting
TSP — transeptal puncture 
tive oral anticoagulation needs to be fixed for at least 
3 weeks before the procedure or transesophageal 
echocardiography (TEE) has to be performed to rule 
out left atrial thrombi [4, 129, 130]. After cardiover-
sion, oral anticoagulation is mandatory for at least 
another 4 weeks for all patients [1, 4, 130].
Single NOAC dose ≥ 4 hours before cardio-
version (≥ 2 h after apixaban loading dose) is safe 
and effective in patients with AF of ≥ 48 hours 
duration, provided that TEE is performed prior to 
cardioversion [1]. A similar strategy of initiating 
a NOAC before cardioversion, with a TEE depend-
ent on institutional policy or patient-related stroke 
risk, is applicable to those with AF of ≥ 48 hours 
duration [131–133].
Patients with thrombus on TEE cardioversion 
should be postponed. Treatment with VKA is stand-
ard management in this scenario. However, NOACs 
may be also considered an option, especially in 
patients in whom VKAs are poorly tolerated or 
adequate INR control cannot be achieved [9, 134].
Frail and elderly patients should  
not be undertreated: NOACs  
in special clinical scenarios
NOACs in frail and older patients
A meta-analysis that included data for all four 
NOACs investigated in the phase 3 RCTs suggests 
the lack of age influence on the NOAC efficacy/safety 
profile [135]. In older patients, higher absolute risk 
resulted in the larger absolute risk reduction when 
using NOACs instead of VKA. Additionally, there 
was a lower number needed to treat compared to 
younger patients [136]. Although bleeding rate 
was higher in elderly patients, the overall pattern 
of bleedings comprising reduced intracranial and 
increased GI bleeding showed no difference between 
NOACs and VKA. The rate of intracranial bleedings 
is lower with all NOACs vs. VKA [135].
Frailty and falls
According to the EHRA experts frailty should not 
exclude patients from treatment with anticoagulants. 
Of note, frail and older patients are at an increased risk 
of stroke and have the biggest benefit from oral antico-
agulation [1, 137]. In this particular patient subset, the 
benefit of NOACs vs. VKA has best been documented 
for edoxaban and apixaban [138, 139]. To improve 
the situation, all falling patients on oral anticoagulant 
should be carefully assessed by multidisciplinary 
team assessment to address the risks and remediable 
pathology to minimize the risk of further falls [1, 140].
Dementia and anticoagulation
Dementia should not be an exclusion exclusion 
criterion to anticoagulation therapy [141, 142].
Obesity
There is very scarce data with respect to 
anticoagulation therapy in extreme obesity, thus, 
the use of VKA in patients with a body mass index 
≥ 40 kg/m2 or weight > 120 kg should be consid-
ered [143, 144]. In cases when a NOAC is required 
in obese patients, specific measurements of drug 
trough levels should be considered [1].
Low body weight
Severely underweight patients, i.e. < 50 kg, 
were underrepresented in large RCTs. Even for 
apixaban and edoxaban that were dose-adjusted 
based on body weight, data are limited for this 
particular subset [1]. On the other hand, VKA 
therapy may substantially increase bleeding risk 
in underweight patients [145]. If therapy with 
a NOAC is warranted in these individuals, meas-
urement of trough levels may be considered to 
check for drug accumulation [146]. 
Women of reproductive age
All cases of abnormal uterine bleeding on 
anticoagulation require assessment for underlying 
structural problems and potential local hormonal 
therapy or surgical procedures to reduce the risk 
of recurrence of abnormal uterine bleeding. Im-
portantly, due to the lack of data on their safety, all 
NOACs are contraindicated in pregnancy as well 
as during breastfeeding [1].
NOACs in athletes
Undoubtedly, athletes on anticoagulation 
should avoid contact sports. Limited evidence ex-
ists on the use of NOACs in such patients. Theoret-
ically, the use of an once daily agent administered in 
the evening may be advantageous in athletes. Such 
a regimen allows to avoid high NOAC concentra-
tions during the actual exercise [1].
Epilepsy
Epilepsy is a relatively frequent disease es-
pecially in population after stroke. Patients who 
suffer generalized seizures are particularly vul-
nerable to head trauma. Notably, tongue biting is 
a risk of bleeding [147, 148]. Since anticoagulation 
is strongly affected by antiepileptic drugs [48], in 
some scenarios, NOACs may not be the preferred 
choice [1].
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Anticoagulation in patients with a malignancy
Anticoagulation therapy in population with 
cancer stands for a very important clinical prob-
lem. Nevertheless, the data is scarce. Of note, 
HOKUSAI-VTE Cancer trial comparing edoxaban 
with LMWH targeted cancer patients with venous 
thromboembolic disease (VTE) but not AF [149]. 
Edoxaban was non-inferior with regard to the pri-
mary endpoint of recurrent VTE and major bleeding. 
Recurrent VTE tended to be reduced with edoxaban, 
major bleeding — due to elevated event rates of GI 
bleeding in patients with GI cancer — was higher 
[149]. Also several meta-analyses including VTE 
trials reported similar or better efficacy of NOACs 
in comparison to VKA or LMWH for VTE preven-
tion in small cancer populations, although major 
bleeding rates were higher [150]. Further research 
is required to investigate the application of these 
findings to AF subset with malignancy. Further-
more, drug–drug interactions between NOACs and 
specific chemotherapeutic agents are still not fully 
understood [1, 151].
Summary: New EHRA guide highlights 
and take home messages
Although NOACs have emerged as the pre-
ferred choice, many unresolved questions remain. 
Herein, we present several key messages provided 
by an updated “EHRA Practical Guide” essentially 
improving our knowledge and confidence in the 
clinical routine: 
1. The strategy with NOACs can be used in pa-
tients with VHD. NOACs are not recommended 
in patients after mechanical valve implantation 
or mitral stenosis of rheumatic origin.
2. The EHRA NOAC card should be distributed 
to patients on NOACs both at initiation and 
during follow-up.
3. Proper education by improvement of know-
ledge and implementation of technological aids 
should be used to optimize adherence to the 
prescribed NOACs, including dedicated mobile 
applications with decision support systems. 
4. Tested standard doses of NOACs should be 
recommended to provide optimal benefit for 
the patient. Dose reduction of NOACs should 
be carefully discussed and based on the dose re-
duction criteria used in the large phase 3 RCTs.
5. Drug–drug interactions should be carefully 
checked in every patient before the strategy 
with NOAC is recommended. 
6. Renal function should be assessed using CrCl 
preferably estimated by the Cockroft-Gault 
formula. The minimum frequency of renal 
function testing in months may be calculated 
by dividing CrCl by 10.
7. Routine assessment of NOAC plasma levels 
is not obligatory and should be limited to 
particular situations like emergencies (se-
vere bleeding, urgent surgery, and stroke) 
or complex patient profiles (e.g. multiple rel-
evant drug–drug interactions, severe over-/ 
/underweight or reduced kidney function) and 
should be performed under the guidance of 
a coagulation expert.
8. The use of NOACs with antiplatelet therapy 
is feasible, safe and preferred over VKA, how-
ever triple therapy with potent P2Y12 inhibitors 
should be avoided (prasugrel, ticagrelor).
9. Endovascular thrombectomy is the ‘first line 
strategy’ in a subjects with contraindications 
to thrombolysis by the European Stroke Or-
ganization. 
10. Thrombolysis with rt-PA can be used when no 
NOAC effect can be assumed by specific co-
agulation assays or after NOAC effect reversal.
11. Frail and elderly patients should not be un-
dertreated. NOACs are safe and efficient in 
high-risk subsets
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